Latest / The Peptide Research Podcast / Episode 70: Retatrutide Dosing: What the Research Says

Transcript

Episode 70: Retatrutide Dosing: What the Research Says · The Peptide Research Podcast

• 0:45
  SPEAKER_01: Ever wondered why the scientific world is absolutely buzzing about a single metabolic compound that's completely rewriting how researchers think about weight loss?
• 0:54
  SPEAKER_01: Well, today we're unpacking the exact dosing strategies behind retitrutide, the so-called triple G molecule that's shattering old clinical benchmarks.
• 1:04
  SPEAKER_01: Welcome back to the peptideresearch.us podcast, brought to you by NRG Biolabs.
• 1:09
  SPEAKER_01: I'm Amy Andrews, and as always, I'm joined by our expert research coordinator, Todd Collins.
• 1:14
  SPEAKER_01: Today we're diving deep into the fascinating clinical trial protocols of retitrutide.
• 1:19
  SPEAKER_01: And if you want to follow along with full data breakdowns and research articles, head right over to peptideresearch.us.
• 1:26
  SPEAKER_00: Great to be here, Amy.
• 1:27
  SPEAKER_00: Yeah, retitrutide is a genuine shift in metabolic science, because unlike older single or dual receptor compounds, retitrutide activates three distinct hormone pathways simultaneously: GLP1, GIP, and glucagon, which is why the scientific community calls it a triple receptor agonist.
• 1:46
  SPEAKER_00: Today we're going to break down exactly how researchers structured the target doses, from one milligram all the way up to 12 milligrams, and why the secret to its remarkable results lies in how subjects escalated to those doses.
• 1:59
  SPEAKER_01: I can't wait to dive into the mechanics, but before we go any further, let's lay down our foundation.
• 2:04
  SPEAKER_01: All peptides discussed in this podcast relate to research use only.
• 2:09
  SPEAKER_01: Any references to data from animals, cells, or human studies relate exclusively to scientific literature and not to products from NRG biolabs.
• 2:17
  SPEAKER_01: These compounds are not approved drugs or dietary supplements and are not for human consumption.
• 2:22
  SPEAKER_01: Nothing in this podcast is medical advice.
• 2:25
  SPEAKER_01: Okay, Todd, let's start with the absolute basics here.
• 2:28
  SPEAKER_01: What actually is retitrutide, and why does adding that third receptor make such a massive difference in research settings?
• 2:35
  SPEAKER_00: Think of early metabolic research like a simple tune.
• 2:38
  SPEAKER_00: Symaglide targets GLP1.
• 2:41
  SPEAKER_00: That's one instrument playing a clear melody to slow down gastric emptying and tell the brain you're full.
• 2:47
  SPEAKER_00: Then came trusepitide, which added GIP, a second instrument harmonizing to enhance insulin sensitivity and fat metabolism.
• 2:55
  SPEAKER_00: But retatrutide brings in a third instrument, glucagon receptor signaling, creating a full biological symphony.
• 3:02
  SPEAKER_00: Glucagon is fascinating because while GLP1 and GIP manage appetite and glucose handling, glucagon actually signals the liver to increase energy expenditure and burn stored lipids.
• 3:15
  SPEAKER_01: Oh wait, that's wild.
• 3:16
  SPEAKER_01: So GLP1 and GIP reduce energy input, while glucagon actively increases energy output.
• 3:24
  SPEAKER_01: It's like simultaneously easing off the brakes and hitting the gas pedal on metabolic weight.
• 3:29
  SPEAKER_00: That's a great analogy, Amy, and that exact dual action mechanism is why researchers are seeing unprecedented numbers in clinical trials.
• 3:36
  SPEAKER_00: But here's the catch that scientists quickly realized: if you activate three major metabolic receptors at once, you can't just jump straight to the maximum concentration.
• 3:46
  SPEAKER_00: You have to train the biological system to adapt.
• 3:49
  SPEAKER_01: Right.
• 3:50
  SPEAKER_01: Which brings us to the core question researchers keep asking.
• 3:53
  SPEAKER_01: What doses of retrutide have actually been evaluated in these major trials?
• 3:58
  SPEAKER_00: Let's break it into three distinct parts.
• 4:01
  SPEAKER_00: The what, the analogy, and the why it matters.
• 4:04
  SPEAKER_00: First, the what.
• 4:05
  SPEAKER_00: In phase two, researchers evaluated weekly target doses of 1 milligram, 4 milligrams, 8 milligrams, and 12 milligrams.
• 4:13
  SPEAKER_00: Moving into phase 3, the Triumph trials, they focused primarily on target doses of 4 mg, 9 milligrams, and 12 milligrams, administered once weekly as subcutaneous injections.
• 4:25
  SPEAKER_00: Now, second, for the analogy, think of escalating retrutide like climbing a high-altitude mountain.
• 4:31
  SPEAKER_00: If you fly a helicopter straight to the 12 mg summit, your body experiences acute altitude sickness, gastrointestinal distress like nausea or diarrhea.
• 4:41
  SPEAKER_00: But if you establish base camps along the way, starting low and stepping up every four weeks, your body acclimates effortlessly.
• 4:49
  SPEAKER_01: I see.
• 4:50
  SPEAKER_01: So the biological system needs time to build tolerance to that intense triple receptor activation.
• 4:56
  SPEAKER_01: Otherwise, you get a metabolic traffic jam where subjects forced to drop out of the study early on.
• 5:02
  SPEAKER_00: Exactly.
• 5:03
  SPEAKER_00: And here's a quick lab insight.
• 5:04
  SPEAKER_00: Early in phase two, researchers tested starting some subjects at 4 mg right away, while others started at 2 milligrams.
• 5:12
  SPEAKER_00: In the lab models and clinical data, researchers saw a dramatic difference.
• 5:17
  SPEAKER_00: Subjects starting at 2 milligrams had significantly lower rates of gastrointestinal disruption.
• 5:23
  SPEAKER_00: That single insight transformed how phase 3 was designed.
• 5:27
  SPEAKER_00: In the Triumph 1 trial, every single retotrutide group started at a gentle 2 milligram base dose for the first four weeks before stepping up through intermediate levels like 4 milligrams and 6 milligrams every four weeks until reaching their assigned target dose of 4, 9, or 12 milligrams.
• 5:45
  SPEAKER_01: That step-down starting approach makes total sense.
• 5:48
  SPEAKER_01: It's like easing into a cold pool instead of diving headfirst into the deep end.
• 5:52
  SPEAKER_01: And speaking of high standards and precise stepping, that attention to detail and research protocols is exactly why high purity materials are paramount.
• 6:01
  SPEAKER_01: Whenever researchers explore complex pathways, having verifiable analytical standards is crucial.
• 6:08
  SPEAKER_01: That's why our sponsor, NRG Biolabs, is dedicated to providing absolute transparency with comprehensive third-party COAs for every lot.
• 6:17
  SPEAKER_01: When you want to review the highest research standards and verify analytical purity yourself, be sure to visit peptideresearch.us.
• 6:24
  SPEAKER_00: Reliable data always begins with uncompromised compound purity, Amy.
• 6:28
  SPEAKER_00: And when you look at the results under those controlled escalation protocols, the weight reduction data was remarkable.
• 6:34
  SPEAKER_00: In phase two, at 48 weeks, the average bodyweight reduction showed a distinct dose-dependent curve.
• 6:41
  SPEAKER_00: 1 milligram produced 8.7% reduction, 4 milligrams hit 17.1%, 8 milligrams reached 22.8%, and 12 milligrams reached an astounding 24.2% reduction, which translated to over 70 pounds on average.
• 6:58
  SPEAKER_01: Wow, nearly a quarter of total body weight at the 12 milligram target dose.
• 7:03
  SPEAKER_01: Did phase three back up those massive numbers?
• 7:06
  SPEAKER_00: It actually exceeded them over longer durations.
• 7:09
  SPEAKER_00: In Triumph 1, at 80 weeks, participants assigned to the 4 milligram target dose lost an average of 19.0% of their body weight.
• 7:18
  SPEAKER_00: The 9 milligram group achieved 25.9%, and the 12 milligram group reached a staggering 28.3% average weight reduction, which translated to over 70 pounds on average.
• 7:31
  SPEAKER_00: In extended follow-ups for higher BMI cohorts, researchers even observed average reductions reaching up around 30.3% at 104 weeks.
• 7:40
  SPEAKER_01: Oh, wait, so why do people care so much about this specific compound compared to existing options?
• 7:47
  SPEAKER_01: It's not just the scale number, right?
• 7:49
  SPEAKER_01: What is it about the quality of that weight loss that has human metabolism researchers so thrilled?
• 7:54
  SPEAKER_00: Receiving that subjective input, Amy, researchers are observing that the addition of glucagon activity appears to target visceral fat stores aggressively while helping preserve lean muscle tissue, which is historically a huge hurdle during severe caloric deficits.
• 8:08
  SPEAKER_00: Plus, the energetic expenditure lift from glucagon signaling helps prevent the typical metabolic slowdown that happens when someone loses significant mass.
• 8:17
  SPEAKER_01: So it essentially protects muscle while torching fat and keeping metabolic speed elevated.
• 8:23
  SPEAKER_01: No wonder every lab in the country is studying this triple agonist.
• 8:27
  SPEAKER_00: Precisely.
• 8:28
  SPEAKER_00: But remember, 12 milligrams isn't a universal maximum.
• 8:31
  SPEAKER_00: It was simply the highest target dose evaluated in these specific clinical trials.
• 8:36
  SPEAKER_00: Because tolerability varies, about 11.3% of subjects in the 12 milligram group discontinued due to side effects, compared to just 4.1% in the 4 milligram group, proving that higher isn't always better for every individual system, and that stepwise escalation remains mandatory for safety and retention.
• 8:55
  SPEAKER_01: Let's recap what we've learned today, folks.
• 8:57
  SPEAKER_01: Retitrutide is a revolutionary triple G compound targeting GLP1, GIP, and glucagon receptors.
• 9:05
  SPEAKER_01: Clinical trials evaluated weekly target doses from 1 milligram to 12 milligrams, with phase 3 focusing on 4 milligrams, 9 milligrams, and 12 milligrams.
• 9:15
  SPEAKER_01: And crucial trial lessons showed that starting at a gentle 2 milligram base dose and escalating every four weeks is essential for managing tolerability while achieving up to 28.3% average weight loss.
• 9:29
  SPEAKER_00: Oh, and one last thing that's easy to overlook.
• 9:31
  SPEAKER_00: Remember that milligram amounts cannot be translated between different compounds.
• 9:36
  SPEAKER_00: A 10 milligram dose of terzepitide does not equal 10 milligrams of retitrutide because their receptor binding affinities and overall biological mechanisms are entirely distinct.
• 9:47
  SPEAKER_01: Such a crucial distinction, Todd.
• 9:49
  SPEAKER_01: If you want to dive deeper into the comparative breakdowns between dual and triple receptor agonists, check out all our deep dive research guides over at peptideresearch.us.
• 9:58
  SPEAKER_01: If you like this podcast and want to stay up to date on all the latest peptide research, you can find links to our website, Facebook page, and even our Discord channel in the podcast description below.
• 10:08
  SPEAKER_01: You can even sign up for our newsletter and get notified every time a new episode rolls out.
• 10:12
  SPEAKER_01: Thanks for listening, and we'll see you next time.